Biomarkers in the Evaluation of Chronic Lung Disease
Public ClinicalTrials.gov record NCT00926523. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic inflammatory process, and that MIF may be a useful biomarker of the severity and progression of both ILD and PH.
Study identification
- NCT ID
- NCT00926523
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 67 participants
Conditions and interventions
Interventions
- Blood Gas Other
- Pulmonary Exercise Test Other
- Spirometry Other
- Breath Condensate Collector Other
Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2009
- Primary completion
- Feb 28, 2011
- Completion
- Feb 28, 2011
- Last update posted
- May 26, 2011
2009 – 2011
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Interstitial Lung Disease and Pulmonary Hypertension Programs | New Hyde Park | New York | 11040 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Pulmonary Hypertension trials
Other public records listing Pulmonary Hypertension. Sorted by last update posted; newest first. Not a recommendation.
- NCT07123779: HS235 Study in Obese Participants With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF) Recruiting
- NCT07234032: An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Recruiting
- NCT04991454: Xenon MRI Pulm Hypertension Recruiting
- NCT07561034: The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease Recruiting
- NCT06336798: Bioenergetic Effect of Pioglitazone in CLD-PH Recruiting
- NCT01730092: Natural History Study of Biomarkers in Pulmonary Arterial Hypertension Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00926523, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 26, 2011 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00926523 live on ClinicalTrials.gov.